In metastatic EGFRm NSCLC
Once-daily TAGRISSO can be taken any time of day,* with or without food1
*At the same time each day.
For patients who have difficulty swallowing pills1
EGFRm, epidermal growth factor receptor mutant; NG, nasogastric; NSCLC, non-small cell lung cancer.
Reference: 1. TAGRISSO [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2019.
TAGRISSO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test.
Please see complete Prescribing Information including Patient Information.
You may report side effects related to AstraZeneca products by clicking here.